IMNP - Immune Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0032
-0.0021 (-39.62%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.0053
Open0.0045
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0023 - 0.0051
52 Week Range0.0023 - 0.0051
Volume29,099,001
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire5 months ago

    Immune Pharmaceuticals Files for Chapter 11 Protection

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, has filed for chapter 11 bankruptcy in the Federal Bankruptcy Court in New Jersey. Despite making significant progress towards a bertilimumab strategic transaction, with the partnering process already yielding term sheets, Immune was unable to negotiate terms for additional funding to provide the several month’s runway necessary to complete a transaction.  The Company had expected to receive $3 million in financing and to sign a Ceplene partnership with an initial payment of $2.5 million, but neither transaction closed.  Accordingly, in order to prevent the loss of the Company’s assets, the Company undertook the difficult decision to seek the protection of the bankruptcy court.

  • GlobeNewswire7 months ago

    Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab Strategic Transaction

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or “the Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that it has engaged Extera Partners to lead the Company’s ongoing effort to secure a partnership for bertilimumab, a phase 2, first-in-class, fully human anti-eotaxin-1 monoclonal antibody. Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

  • GlobeNewswire8 months ago

    Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders

    IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that its Special Meeting of Stockholders, held on December 5, 2018, was adjourned until December 19, 2019, at 9:30 a.m. Eastern Time. The Adjourned Meeting will be held at the offices of the Company’s counsel, Lowenstein Sandler LLP, at One Lowenstein Drive, Roseland, New Jersey 07068. A quorum was present for the authorization of the Special Meeting, as more than one-third of the issued and outstanding shares entitled to vote as of the record date were represented in person or by proxy.

  • GlobeNewswire8 months ago

    Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, and Vector Therapeutics, Inc. (“Vector”), a biopharmaceutical company acquiring, developing and commercializing oncology therapeutics, today announced the execution of an agreement that gives Vector an option to acquire worldwide rights to Ceplene. Under the option agreement, Vector has paid Immune $500,000 and has gained an exclusive option to acquire worldwide Ceplene rights for total additional fixed consideration of $14.5 million, including $2.5 million at closing, $4.5 million in 2019, and $2.5 million in each of 2020, 2021 and 2022.  At closing, Vector will also assume certain Ceplene-related liabilities from Immune, expected to total approximately $3.5 million.

  • GlobeNewswire8 months ago

    Immune Pharmaceuticals Reschedules Corporate Update Call

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, is delaying its corporate call until after the holiday week in order to provide a more comprehensive shareholder update.  The call will now take place on Tuesday, November 27 at 8:30 am Eastern Time. Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that targets eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation.

  • GlobeNewswire8 months ago

    Immune Pharmaceuticals Schedules Corporate Update Call

    Immune Pharmaceuticals, Inc. (IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, will provide a corporate update on Tuesday, November 20 at 8:30 am Eastern Time. On the call, Tony Fiorino, interim Chief Executive Officer of Immune, will provide an update on various corporate matters, including the bertilimumab clinical development program, the company’s finances, and the forthcoming special meeting of stockholders, scheduled for December 5, 2018. The live webcast will be available on the Events page of the Investors section of the Company’s website (http://www.immunepharma.com/), and will be archived for 60 days.